Bone Effects of Subcutaneous Teriparatide Following Discontinuation of Alendronate Treatment in Postmenopausal Women With Osteoporosis
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Teriparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 30 Oct 2005 New trial record.